Steward Partners Investment Advisory LLC Purchases 5,107 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Steward Partners Investment Advisory LLC increased its stake in Gilead Sciences by 11.1%, now owning over 50,000 shares valued at approximately $5.7 million.
• Gilead recently reported quarterly earnings of $2.01 EPS, surpassing estimates, with revenues of $7.08 billion, a year-over-year increase of 1.4%.
• The company declared a quarterly dividend of $0.79, representing a 2.7% yield, to be paid on September 29th to shareholders on record by September 15th.

Steward Partners Investment Advisory LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 50,925 shares of the biopharmaceutical company's stock after purchasing an additional 5,107 shares during the quarter. Steward Partners Investment Advisory LLC's holdings in Gilead Sciences were worth $5,706,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in GILD. Redwood Financial Network Corp grew its stake in shares of Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after buying an additional 98 shares in the last quarter. Argentarii LLC grew its stake in shares of Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after buying an additional 99 shares in the last quarter. Peak Financial Advisors LLC lifted its holdings in Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock worth $677,000 after purchasing an additional 100 shares during the last quarter. Perkins Coie Trust Co lifted its holdings in Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock worth $435,000 after purchasing an additional 100 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. lifted its holdings in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

GILD has been the subject of a number of research analyst reports. Morgan Stanley upped their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Royal Bank Of Canada upped their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. Finally, Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Trading Down 2.2%

GILD traded down $2.59 during midday trading on Thursday, reaching $116.14. 6,062,069 shares of the company were exchanged, compared to its average volume of 6,678,418. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a one year low of $75.35 and a one year high of $121.83. The stock has a market capitalization of $144.11 billion, a P/E ratio of 23.14, a PEG ratio of 0.73 and a beta of 0.33. The stock's 50-day simple moving average is $112.41 and its 200 day simple moving average is $108.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter last year, the business earned $2.01 earnings per share. The company's revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is 62.95%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the sale, the chief executive officer owned 605,725 shares in the company, valued at $69,016,306.50. The trade was a 1.62% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock worth $9,339,230. Company insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.